EAACI Congress 2025
BackTPS06 - Asthma 01
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)
Dupilumab-induced eosinophilia: a transient effect
Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
Identification of rBlo t 41 with a Chitin-binding type-2 domain: a Novel Major Allergen from Blomia tropicalis
Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)
Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients
MV130 drives the differentiation of human monocytes into dendritic cells with antiallergic properties
Mepolizumab and intestinal parasitic infection: A case report
Mepolizumab in severe asthmatic patients with EGPA, long-term real-life data
Remission of asthma on biological therapy: one center experience
Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe
The treatment of eosinophilic asthma with mepolizumab and benralizumab: relative effectiveness
